Qiagen N.V. (NYSE:QGEN) to Issue Dividend Increase – $0.35 Per Share

Qiagen N.V. (NYSE:QGEN) declared an annual dividend on Tuesday, May 12th. Stockholders of record on Tuesday, July 7th will be given a dividend of 0.35 per share on Tuesday, July 14th. This represents a dividend yield of 104.0%. The ex-dividend date is Tuesday, July 7th. This is a 33.0% increase from Qiagen’s previous annual dividend of $0.26.

Qiagen has a payout ratio of 10.3% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Qiagen to earn $2.69 per share next year, which means the company should continue to be able to cover its $0.26 annual dividend with an expected future payout ratio of 9.7%.

Qiagen Trading Up 3.2%

QGEN stock traded up $1.04 on Tuesday, reaching $33.67. The company’s stock had a trading volume of 3,286,218 shares, compared to its average volume of 2,318,762. The business has a fifty day simple moving average of $40.29 and a two-hundred day simple moving average of $46.12. Qiagen has a 12-month low of $32.60 and a 12-month high of $57.81. The firm has a market cap of $6.94 billion, a PE ratio of 17.58, a PEG ratio of 3.29 and a beta of 0.64. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. The firm had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.09%. During the same period last year, the company posted $0.56 EPS. As a group, research analysts forecast that Qiagen will post 2.43 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their price target on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. Citigroup cut their target price on shares of Qiagen from $55.00 to $38.00 and set a “neutral” rating for the company in a research report on Wednesday, April 29th. Barclays set a $38.00 price target on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the company a “hold” rating in a research report on Friday, February 6th. Finally, Wall Street Zen cut Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $46.38.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.